Biotechnology Valuation: An Introductory Guide Biotechnology is producing quantum advances in medicine, but the specter of unforeseen consequences from treatments has brought with it a parallel growth in litigation.  Valuing biotechnology assets isn’t easy: generally accepted methods of discounted cash flows (DCF) and market comparison are sometimes difficult to apply in an industry rife with low probabilities of success, variable marketability, and patent lives shortened by the drug development and regulatory process.  Karl D. Keegan’s Biotechnology Valuation: An Introductory Guide helps consultants navigate this growing field. Lari Masten reviews.